Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 352

1.

NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer.

Zippe C, Pandrangi L, Agarwal A.

J Urol. 1999 Jan;161(1):62-5.

PMID:
10037369
2.

NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer.

Zippe C, Pandrangi L, Potts JM, Kursh E, Novick A, Agarwal A.

Anticancer Res. 1999 Jul-Aug;19(4A):2621-3.

PMID:
10470205
3.
4.

Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder.

Stampfer DS, Carpinito GA, Rodriguez-Villanueva J, Willsey LW, Dinney CP, Grossman HB, Fritsche HA, McDougal WS.

J Urol. 1998 Feb;159(2):394-8. Erratum in: J Urol 1998 May;159(5):1650.

PMID:
9649246
5.

Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment.

Soloway MS, Briggman V, Carpinito GA, Chodak GW, Church PA, Lamm DL, Lange P, Messing E, Pasciak RM, Reservitz GB, Rukstalis DB, Sarosdy MF, Stadler WM, Thiel RP, Hayden CL.

J Urol. 1996 Aug;156(2 Pt 1):363-7.

PMID:
8683680
6.

Screening and monitoring for bladder cancer: refining the use of NMP22.

Ponsky LE, Sharma S, Pandrangi L, Kedia S, Nelson D, Agarwal A, Zippe CD.

J Urol. 2001 Jul;166(1):75-8.

PMID:
11435827
7.

NMP22 in transitional cell carcinoma of the urinary bladder.

Su CK, Yang CR, Horng YY, Kao YL, Ho HC, Ou YC, Cheng CL.

J Chin Med Assoc. 2003 May;66(5):294-8.

PMID:
12908572
9.

Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.

Sawczuk IS, Bagiella E, Sawczuk AT, Yun EJ.

Cancer Detect Prev. 2000;24(4):364-8.

PMID:
11059567
10.

Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology.

Shariat SF, Casella R, Wians FH Jr, Ashfaq R, Balko J, Sulser T, Gasser TC, Sagalowsky AI.

Eur Urol. 2004 Mar;45(3):304-13; author reply 313.

PMID:
15036675
11.

Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.

Kumar A, Kumar R, Gupta NP.

Jpn J Clin Oncol. 2006 Mar;36(3):172-5. Epub 2006 Mar 6.

PMID:
16520358
12.
13.

The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer.

Shariat SF, Casella R, Monoski MA, Sulser T, Gasser TC, Lerner SP.

J Urol. 2003 Dec;170(6 Pt 1):2244-7.

PMID:
14634389
14.

Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat.

Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A.

J Urol. 1999 Jul;162(1):53-7.

PMID:
10379739
15.

Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer.

Sánchez-Carbayo M, Urrutia M, Silva JM, Romaní R, De Buitrago JM, Navajo JA.

J Urol. 2001 May;165(5):1462-7.

PMID:
11342897
16.
17.

[Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--screening for urothelial cancer in patients with microscopic hematuria. NMP Study Group].

Akaza H, Miyanaga N, Tsukamoto T, Ishikawa S, Noguchi R, Ohtani M, Kawabe K, Kubota Y, Fujita K, Obata K, Hirao Y, Kotake T, Ohmori H, Kumazawa J, Koiso K.

Gan To Kagaku Ryoho. 1997 May;24(7):837-42. Japanese.

PMID:
9170522
18.

Evaluation of the clinical value of urinary NMP22 as a marker in the screening and surveillance of transitional cell carcinoma of the urinary bladder.

Chahal R, Darshane A, Browning AJ, Sundaram SK.

Eur Urol. 2001 Oct;40(4):415-20; discussion 421.

PMID:
11713396
19.

Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.

Giannopoulos A, Manousakas T, Gounari A, Constantinides C, Choremi-Papadopoulou H, Dimopoulos C.

J Urol. 2001 Aug;166(2):470-5.

PMID:
11458049
20.

Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.

Svatek RS, Herman MP, Lotan Y, Casella R, Hsieh JT, Sagalowsky AI, Shariat SF.

Cancer. 2006 Apr 15;106(8):1701-7.

Supplemental Content

Support Center